INVOKAMET XR Drug Patent Profile

When do Invokamet Xr patents expire, and what generic alternatives are available?

Invokamet Xr is a drug marketed by Janssen Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty patent family members in forty-five countries.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Invokamet Xr

Invokamet Xr was eligible for patent challenges on March 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 14, 2028. This may change due to patent challenges or generic licensing.

There have been thirty-three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INVOKAMET XR

International Patents:	220
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVOKAMET XR

Paragraph IV (Patent) Challenges for INVOKAMET XR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKAMET XR	Extended-release Tablets	canagliflozin; metformin hydrochloride	50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	205879	1	2018-11-21

US Patents and Regulatory Information for INVOKAMET XR

INVOKAMET XR is protected by three US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-004	Sep 20, 2016		RX	Yes	Yes					Y

International Patents for INVOKAMET XR

See the table below for patents covering INVOKAMET XR around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	536863
Australia	2002337974
Canada	2409999	MELANGES DE POLYMERES OPTIQUES POUR DES COMPRIMES POUVANT ETRE RETENUS DANS L'ESTOMAC (OPTICAL POLYMER MIXTURES FOR GASTRIC RETENTIVE TABLETS)
European Patent Office	1446106	MÉLANGES DE POLYMÈRES OPTIMAUX POUR COMPRIMÉS A RÉTENTION GASTRIQUE (OPTIMAL POLYMER MIXTURES FOR GASTRIC RETENTIVE TABLETS)
European Patent Office	2260832

Supplementary Protection Certificates for INVOKAMET XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1651658	637	Finland
1651658	CR 2014 00024	Denmark		PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119
1651658	164 1-2014	Slovakia		PRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115
1651658	C 2014 017	Romania		PRODUCT NAME: CANAGLIFLOZIN; NATIONAL AUTHORISATION NUMBER: EU/1/13/884; DATE OF NATIONAL AUTHORISATION: 20131115; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/884; DATE OF FIRST AUTHORISATION IN EEA: 20131115
1651658	SPC/GB14/032	United Kingdom		PRODUCT NAME: CANAGLIFLOZIN; REGISTERED: UK EU/1/13/884/001 20131119; UK EU/1/13/884/002 20131119; UK EU/1/13/884/003 20131119; UK EU/1/13/884/004 20131119; UK EU/1/13/884/005 20131119; UK EU/1/13/884/006 20131119; UK EU/1/13/884/007 20131119; UK EU/1/13/884/008 20131119

Last updated: July 5, 2026

INVOKAMET XR investment scenario and fundamentals analysis (Invokana XR combination of canagliflozin + metformin ER)

Executive summary: INVOKAMET XR (canagliflozin/extended-release metformin) is a niche branded combination in the SGLT2 inhibitor and type 2 diabetes (T2D) market. Core investment exposure is driven by (1) the pace of generic and authorized generic erosion of branded metformin XR and branded canagliflozin-containing combinations, (2) the substitution effect toward single-agent SGLT2 inhibitors and fixed-dose combinations (FDCs) with stronger payer positioning, and (3) the probability that the remaining brand franchise is supported by switch-driving evidence, formulary durability, and contract pricing. With patent and exclusivity barriers largely behind the canagliflozin class in the US, INVOKAMET XR’s fundamentals are best evaluated as a commercial and contracting problem rather than a long-dated IP-backed growth story.

---

What is INVOKAMET XR and how does it fit into type 2 diabetes treatment guidelines?

Quick answer: INVOKAMET XR combines canagliflozin (SGLT2 inhibitor) with metformin extended-release (ER) for T2D. It targets patients needing glucose control plus renal and cardiovascular risk benefits associated with SGLT2 inhibitors, with metformin providing baseline glycemic efficacy.

Mechanism and value proposition

• Canagliflozin: lowers glucose by inhibiting renal SGLT2; adds cardiometabolic and renal outcomes benefit in appropriate populations.
• Metformin ER: reduces hepatic gluconeogenesis and improves insulin sensitivity; remains the backbone of T2D therapy in most guidelines.

Clinical use pattern

• Typically initiated when dual therapy is needed and metformin is already part of the regimen.
• Market behavior since class maturation: prescribers often start with an SGLT2 inhibitor or a metformin-containing regimen and later switch into combination products where they reduce pill burden and align with payer tiers.

Where it ranks commercially

• Against single-agent canagliflozin products and other SGLT2/FDC options, INVOKAMET XR competes on “treatment simplification” more than on unique pharmacology.

---

What are the IP and exclusivity timelines for INVOKAMET XR in the US?

Quick answer: For an SGLT2 + metformin FDC like INVOKAMET XR, IP exposure generally shifts from broad composition-of-matter to narrower formulation, salt/crystal form, method-of-use, and combination-specific claims. In practice, US commercial freedom typically arrives through generic entry once key barriers expire and Orange Book-listed patents do not block a Section 505(b)(2)/ANDA strategy.

Investment implication

• Investors should treat INVOKAMET XR as a post-peak brand with diminishing patent-driven moat unless specific, still-live Orange Book patents materially limit ANDA design-arounds.

---

What is the Orange Book status of INVOKAMET XR and which patents are listed for generics challenges?

Quick answer: INVOKAMET XR’s FDA-reviewed IP position is expressed through Orange Book “Active” patents tied to the NDA and product-specific exclusivity. The investment focus is whether any patents remain in force that would deter Paragraph IV ANDAs for the same active ingredients and dosing forms.

Commercial risk lens

• If Orange Book coverage is light or largely design-aroundable, generic and authorized generic pressure accelerates.
• If coverage includes combination-specific method-of-use or formulation patents that are hard to design around, the generic timeline can extend.

Why this matters for valuation

• The revenue durability of INVOKAMET XR is primarily determined by ANDA timing, not by ongoing pipeline optionality.

---

When does INVOKAMET XR lose exclusivity and what launch scenarios matter for investors?

Quick answer: For combination products, “loss of exclusivity” is not a single date. It depends on:

• Patent expiration(s) of Orange Book-listed claims.
• Any unexpired regulatory exclusivities (where applicable).
• Whether remaining patents are still litigated or enforceable against ANDAs targeting the same dosing form (ER tablet).

Launch scenarios

1. Early ANDA entry with design-around: Brand pricing compresses quickly; revenue declines accelerate.
2. Delayed ANDA entry due to litigation: Longer duration of higher pricing; lower near-term erosion rate.
3. Authorized generic strategy: Even if brand receives a partial litigation delay, authorized generics can undercut price and margins.

Investment takeaway

• Base-case valuation should discount for generic encroachment and assume formulary normalization toward cheaper equivalents unless there is evidence-based switch behavior and strong contract pricing.

---

How strong is the patent estate for INVOKAMET XR’s combination and formulations?

Quick answer: Combination products typically rely on a patchwork of:

• Composition claims for canagliflozin/metformin ER combinations (where still enforceable)
• Formulation claims affecting ER release profile, excipients, and tablet structure
• Method-of-use claims related to glycemic control with specific endpoints

Investor grading rubric

• Strong estate: multiple independently enforceable claims across key ANDA design parameters.
• Weak estate: patents are few, narrow, or vulnerable to non-infringing formulations.

What drives differentiation versus generic

• ER-release formulation and manufacturing method constraints can create practical barriers, but only if they are properly claimed and not easily avoided.

---

How many patents cover INVOKAMET XR and who holds them?

Quick answer: Determining “how many patents” and “who holds them” requires Orange Book and patent-family mapping for the specific INVOKAMET XR NDA/product identifiers and dosing strengths. Without the Orange Book dataset and live patent list, the count and ownership cannot be stated accurately for investment-grade use.

---

What patent litigation affects INVOKAMET XR, including Paragraph IV challenges and settlements?

Quick answer: Investment risk depends on whether there are active Paragraph IV suits targeting the INVOKAMET XR NDA and whether settlements delay generic entry.

Key litigation variables

• Number of ANDA filers and asserted patents
• Judge-managed timelines under the Hatch-Waxman framework
• Settlement triggers tied to “at-risk” launch dates

Why this is central for valuation

• A settlement can create predictable revenue cliffs or prolonged brand cash flows depending on entry dates and market scope.

---

Is INVOKAMET XR exposed to biosimilar risk?

Quick answer: No. INVOKAMET XR is a small-molecule combination, not a biologic. Biosimilar risk does not apply.

---

What formulations are protected by INVOKAMET XR’s IP and how does that affect generic substitution?

Quick answer: For metformin ER combinations, the practical substitution question is whether generics can match:

• ER release characteristics
• Tablet composition and excipient system
• Bioequivalence under FDA standards

Generic strategy

• ANDA candidates often design around formulation patents by altering excipients or manufacturing processes while maintaining equivalent release and bioavailability.

Investor implication

• Even if patents remain, generics can still enter “at risk” if patents are found not infringed, invalid, or unenforceable.

---

How does INVOKAMET XR compare with Invokana, metformin ER, and competing SGLT2 combinations?

Quick answer: INVOKAMET XR competes as an SGLT2 + metformin ER FDC. The main alternative set includes:

• Single-agent canagliflozin (Invokana)
• Other SGLT2 + metformin combinations (class comparators)
• Metformin ER plus separate SGLT2 prescriptions

What matters for payer and prescriber

• Total out-of-pocket cost across fills
• Formulary tier placement (preferred vs non-preferred)
• Prior authorization friction and quantity limits
• Clinical inertia: adherence and switch behavior

Competitive pressure

• As class adoption matures and formularies standardize, FDC differentiation shifts from “new drug value” to “contracted cost and convenience.”

---

Which companies are likely competitive threats to INVOKAMET XR’s market share?

Quick answer: Generic firms submitting ANDAs and authorized generic partners are the most relevant threats once Orange Book barriers are weak or expired. Branded competitive threats come from:

• Rival SGLT2/FDC products with better rebate positioning
• Products with dosing flexibility that fits payer formularies

Investment framing

• In mature T2D, rebate economics often outweigh incremental clinical differentiation for most covered populations.

---

What is the FDA status of INVOKAMET XR and what regulatory pathway affects generics entry?

Quick answer: Generic versions typically use ANDA pathways under FDA’s small-molecule framework, targeting bioequivalence and relying on FDA findings for safety and efficacy already supported by the NDA.

Regulatory levers affecting entry timing

• Patent-triggered litigation stays
• Labeling carve-outs for non-infringing labeling
• Launch coordination under settlement agreements

---

What generic entry risks exist for INVOKAMET XR in the US?

Quick answer: Generic entry risk is high when:

• Key Orange Book patents have expired or are narrow and design-aroundable.
• Litigation is resolved or absent.
• Bioequivalence and manufacturing can be achieved for ER tablets without infringing formulation or process claims.

Primary investor risk

• Margin compression from price competition and rebate tightening.

---

How does INVOKAMET XR’s commercial performance translate into revenue exposure?

Quick answer: INVOKAMET XR’s revenue exposure is sensitive to three levers:

1. Share retention: whether clinicians keep patients on the brand FDC versus splitting into components.
2. Net price: contract rebates vs list price erosion.
3. Formulary status: whether payers down-tier it in favor of cheaper FDCs or generics.

Fundamentals to model

• Use declining branded volume curves typical of post-exclusivity FDCs.
• Apply a generic discount schedule that reflects typical rebate negotiations in T2D.

---

Key valuation scenario framework for INVOKAMET XR

Base-case mechanics (post-exclusivity profile)

• Assume gradual share erosion before full generic equivalence, then sharper net-price declines after entry.
• Model additional impact from therapeutic switching toward newer or better-positioned SGLT2 regimens.

Bull case

• Delay in generic entry from enforceable Orange Book patents or litigation-driven stays.
• Sustained formulary position via contracting and clinical familiarity.
• Reduced substitution due to adherence benefits tied to combination dosing.

Bear case

• Early ANDA entry with broad label and effective interchangeability.
• Aggressive pricing by generics and authorized generics.
• Rapid formulary down-tiering.

---

Key Takeaways

• INVOKAMET XR is a mature T2D FDC where the investment thesis is dominated by post-exclusivity erosion dynamics, not long-dated growth.
• The decisive swing factors are Orange Book-listed patents, litigation posture (Paragraph IV), and settlement outcomes that govern generic launch timing and at-risk entry.
• Commercial fundamentals depend on net price via rebates, payer formulary durability, and switching behavior toward cheaper SGLT2 regimens and metformin ER combinations.
• Biosimilar risk is not applicable; the risk map is generic competition plus contracting economics.

---

FAQs

1) What is the typical generic substitution pattern for SGLT2/metformin ER fixed-dose combinations?
After first generic availability, substitution accelerates if the branded product is non-preferred or faces prior authorization friction; otherwise erosion is slower and rebate-driven.

2) How do payer formularies usually treat older metformin ER-based FDCs after SGLT2 class maturation?
They tend to rationalize toward the lowest-cost preferred option, often favoring generics or lower-cost FDCs with better rebate terms.

3) What role do ER formulation bioequivalence issues play in ANDA timing for metformin ER combinations?
They can slow development and testing, but they usually do not prevent entry unless formulation patents are broad and specifically limit permissible release profiles.

4) Does INVOKAMET XR have biologics-type competition risks?
No. It is a small molecule combination and is exposed only to generic/authorized generic competition.

5) What is the most common driver of branded FDC value loss in T2D?
Net price compression driven by rebate and contract renegotiation after generic entry.

---

References (APA)

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. “ANDA (Abbreviated New Drug Application).” U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-applications-anda
3. FDA. “Drug Competition Action Plan.” U.S. Food and Drug Administration. https://www.fda.gov/drugs/competition-and-innovation/drug-competition-action-plan